IQVIA Named Top-Tier Software Vendor by APPS RUN THE WORLD in the APPS and CLOUD TOP 500 Market Report

IQVIA Strengths, Domain Expertise, and Key Differentiators

IQVIA emerged from the merger of IMS Health and Quintiles. Renowned for advanced analytics, technology solutions, and clinical research services, IQVIA facilitates intelligent connections in healthcare. It leverages vast data resources, including over a billion non-identified patient records, spanning sales, prescriptions, medical claims, genomics, and social media.

IQVIA's mission is to provide insightful data and execution capabilities to diverse healthcare stakeholders. This encompasses biotech, pharmaceutical companies, medical researchers, government agencies, and payers. With a repository covering 85% of the world's pharmaceuticals by 2019 sales, IQVIA offers unique, difficult-to-replicate information that propels progress in understanding diseases, human behaviors, and scientific advancements. IQVIA's prominence lies not only in data size but in its unparalleled ability to transform data into actionable insights for the healthcare industry.

IQVIA Recent Developments

IQVIA has entered into a historic collaboration with Alibaba Cloud in China. This marks the first-ever partnership of its kind within the life sciences sector. In this alliance, IQVIA and Alibaba Cloud will provide solutions hosted in Mainland China, leveraging Salesforce on Alibaba Cloud's infrastructure. This collaboration offers customers a pathway to optimize their engagement with clients using the Salesforce platform, recognized for its excellence in the life sciences domain. This groundbreaking partnership signifies a commitment to advancing technological solutions in the rapidly evolving pharmaceutical and life sciences landscape in China.

In September 2021, IQVIA integrated cutting-edge AI-powered technologies into its existing suite of Medical Information (MI) Contact Center services. These services, utilized by life science companies, facilitate the dissemination of information regarding new products, therapeutic areas, and the monitoring of product quality and safety. Operated by skilled agents globally, these MI Contact Center services now leverage AI-powered virtual agents in conjunction with human agents to efficiently triage and respond to inquiries. This strategic combination ensures swifter response times, enhances adverse event reporting, and allows for rapid scalability to meet fluctuating demand, ensuring round-the-clock availability. Spanning more than 170 countries, IQVIA's MI Contact Center services offer multilingual support in 50 languages.

In October 2021, IQVIA inaugurated the Q2 Solutions Innovation Laboratories, a state-of-the-art facility spanning 160,000 square feet. This cutting-edge facility features advanced laboratory capabilities, encompassing bioanalytical, vaccine, biomarker, and genomics laboratories. The site also houses the Translational Science and Innovation Laboratory (TSAIL), offering customers access to a diverse range of services, including a cross-disciplinary approach to early-stage Research & Development and exploratory human biomarker activities. TSAIL is designed to expedite drug development for biopharmaceutical companies.

Furthermore, in July 2020, IQVIA entered into a strategic partnership with AstraZeneca to expedite the development of a potential new vaccine for COVID-19. This collaboration focuses on accelerating clinical studies in the U.S., with the aim of demonstrating the efficacy of AstraZeneca's prospective COVID-19 vaccine. This joint effort reflects IQVIA's commitment to contributing to global healthcare initiatives during critical times.

IQVIA Mergers and Acquisitions (M&A) Activities

In October 2022, IQVIA completed the acquisition of Lasso Marketing, a prominent omnichannel healthcare marketing and analytics platform. Lasso Marketing, founded in 2019 and headquartered in Austin, Texas, specializes in offering end-to-end solutions for planning, executing, measuring, and optimizing consumer-targeted campaigns across various channels, including programmatic, email, social, and connected TV.

In a strategic move announced in April 2021, IQVIA attained full ownership of Q2 Solutions by acquiring the remaining 40 percent minority share previously held by Quest Diagnostics, a global leader in diagnostic information services. Q2 Solutions stands out as a leading global clinical laboratory services organization, delivering comprehensive solutions encompassing testing, project management, supply chain management, biorepository services, and biospecimen and consent tracking solutions tailored for clinical trials.

Additionally, in May 2021, IQVIA extended its industry presence by acquiring a strategic division of Myriad Genetics known as Myriad RBM. This division, now integrated into IQVIA’s Q2 Solutions, specializes in providing contract research services to the pharmaceutical sector. Myriad RBM's expertise lies in screening clinical samples—both diseased and non-diseased—using a comprehensive menu of biomarkers.

It is noteworthy that IQVIA itself was established through the merger of Quintiles and IMS Health in 2016, solidifying its position as a major player in the life sciences and healthcare analytics industry. These strategic acquisitions underscore IQVIA's commitment to expanding its portfolio and enhancing its capabilities to better serve the evolving needs of the healthcare and life sciences sectors.

IQVIA Customers in ARTW Customer Database

Leveraging a rigorous data-centric research methodology, APPS RUN THE WORLD asks the simple question: Who’s buying IQVIA applications and why? And we provide the answers – supported by decades of research – to our clients around the world. Our Customer database has over 100 data fields that detail company usage of IQVIA and other enterprise apps by function, customer size, industry, location, implementation status, partner involvement, Line of Business Key Stakeholders and IT decision makers contact details. List of Verified IQVIA CORE, IQVIA ePromo, Nexxus Mobile Intelligence CRM, IQVIA OCE Sales customers.

IQVIA Key Enterprise and Cloud Applications

IQVIA CORE, IQVIA ePromo, Nexxus Mobile Intelligence CRM, IQVIA OCE Sales

IQVIA Revenues, $M:

IQVIA Revenue Breakdown By Type, $M:

IQVIA Enterprise Applications Revenues By Functional Markets, $M:

IQVIA Enterprise Applications Revenues By Verticals, $M:

IQVIA Revenues By Region, $M

IQVIA Direct vs Indirect sales

IQVIA Customers - Breakdown by Geo, Size, Vertical and Product

List of Verified IQVIA Customers

No. of IQVIA Customers: x

No. of IQVIA Enterprise Applications Customers: x

No. of IQVIA Cloud Customers: x

No. of IQVIA Cloud Subscribers: x

IQVIA boasts a diverse clientele exceeding 10,000 across more than 100 countries. The expansion of our client value proposition strategically targets the expansive market for research and development, as well as commercial operations, estimated to surpass $260 billion in 2020. Predominantly, IQVIA's revenues stem from sales to entities in the life sciences sector, encompassing pharmaceutical, biotechnology, device, diagnostic, and consumer health companies.

Apart from life sciences, our client portfolio includes payers, government and regulatory agencies, providers, pharmaceutical distributors, and pharmacies. In the fiscal years 2020, 2019, and 2018, no single client constituted 10% or more of the total company revenues. As of December 31, 2020, the largest client, based on its percentage contribution to the total company revenue, accounted for approximately 5%. This diversified client base underscores IQVIA's resilience and stability, mitigating dependence on any singular entity for a significant portion of its revenue.

IQVIA Market Opportunities, M&A and Geo Expansions

IQVIA identifies six significant trends shaping their end markets, fostering increased demand for research and development services, technology & analytics solutions, and contract sales and medical solutions. Firstly, the growth and innovation in the life sciences industry, a substantial part of the global healthcare system, estimated to have generated approximately $1.27 trillion in revenue in 2020. Globally, revenue growth in this sector is anticipated to range from 3% to 6% between 2021 and 2025, with pharmaceutical spending in emerging markets expected to expand at a 6% to 9% CAGR through 2025. Secondly, the growth in research and development is influenced by factors like biopharmaceutical companies' efforts to replenish revenues post the "patent cliff," increased access to capital by the small and midcap biotechnology industry, and recent regulatory increases in pharmaceutical approvals. Thirdly, the complexity in research and development has risen due to improved standards of care and the emergence of new therapies, necessitating a more intricate approach. IQVIA, with its global clinical development capabilities and expertise, is poised to assist biopharmaceutical companies in navigating these complexities. Additionally, financial pressures driving the need for increased efficiency, arising from changing product mixes, pricing challenges, and rising compliance costs, make outsourcing arrangements imperative. The evolving need to integrate and structure expanding data sources highlights the challenges in digitizing medical records globally. To derive valuable insights, clients need access to statistically significant data sets organized into queryable databases. Finally, the increasing pressure on life sciences companies to demonstrate the value of their therapies, particularly in the face of new, more expensive drugs, is leading to a heightened focus on sophisticated outcome research and data analytics services. IQVIA believes its strategic positioning and capabilities uniquely position the company to capitalize on these global trends in healthcare, leveraging proprietary information assets and key capabilities to assess opportunities, support the development and commercialization of therapies, and aid clients in efficient decision-making through cost-efficient technology solutions.

IQVIA Risks and Challenges

IQVIA navigates a global pandemic that holds the potential to reshape the life sciences industry in profound ways. The key lies in IQVIA's strategic decisions – whether to capitalize on emerging opportunities through effective partnerships with pharmaceutical companies or risk overextension due to its expansive global reach. The outcome remains uncertain, as IQVIA and its clients grapple with persistent public health challenges.

In this dynamic landscape, a critical consideration is whether IQVIA will opt for substantial acquisitions. This move could either be a well-timed strategic maneuver or result in a Pyrrhic victory, carrying both risks and rewards.

The biopharmaceutical services industry is inherently competitive. IQVIA faces challenges from outsourcing trends, shifts in aggregate spending and research and development budgets, potential healthcare reforms, and regulatory actions that may impact prescription scope or drug market presence, potentially leading to revenue losses. Additionally, clients in the Research & Development Solutions segment contend with fierce competition from lower-cost generic products, potentially impacting their spending on IQVIA's services.

As IQVIA treads through this complex terrain, the strategic decisions made in response to industry dynamics and client needs will play a pivotal role in determining its trajectory amidst the evolving challenges and opportunities within the biopharmaceutical services landscape.

IQVIA Ecosystem, Partners, Resellers and SI

IQVIA Technologies accelerates innovation by building on top of best-in-class platforms and focusing our efforts on differentiation that adds value to life sciences customers. IQVIA customers benefit from access to the best core features, battle-tested code and regular upgrades from standard platforms that are common to their ecosystems. Our products connect all these elements to deliver seamless solutions that are “born-integrated” and tailored to their specific needs. IQVIA is forging some of the most robust technology partnerships in the industry to help achieve this vision. Partners include Salesforce, Accenture, Aprimo, Blue Mountain Quality Resources, DocuSign, Invosys, Riva, Snowflake, and Workday.

IQVIA Cloud Infrastructure Insights

Subscribe to read more about:

• IQVIA Public Cloud and Infrastructure (IaaS)
• IQVIA Platform (PaaS)
• IQVIA Application Delivery
• IQVIA Private Cloud and Data Centers

Research Methodology

Data used in research reports are derived from publicly available documents, continuous surveys of applications vendors, customers, resellers, Independent Software Vendors, systems integrators and other verifiable sources.

Vendor shares and market forecast results are based on a combination of existing databases as well as demand side and supply side research conducted throughout the year with validation from vendors, customers, channel partners and documentations such as earnings releases and 10Q and 10K filings, vertical industry studies, regional and country-level statistics from public and private institutions(i.e. colleges, universities, government agencies and trade associations).

For additional information on our methodologies, here's the link: